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Chronic  hepatitis  B virus  (HBV)  infection  due  to mother-to-child  transmission  (MTCT)  during  perinatal
period  remains  an  important  global  health  problem.  Despite  standard  passive–active  immunoprophy-
laxis  with  hepatitis  B immunoglobulin  (HBIG)  and  hepatitis  B vaccine  in  neonates,  up  to 9% of newborns
still  acquire  HBV  infection,  especially  these from  hepatitis  B  e antigen  (HBeAg)  positive  mothers.  Man-
agement  of  HBV  infection  in pregnancy  still  need  to draw  careful  attention  because  of  some  controversial
aspects,  including  the  failure  of passive-active  immunoprophylaxis  in  a  fraction  of  newborns,  the  effectother to child transmission
mmunoprophylaxis
ntiviral therapy
reastfeeding
and  necessity  of  periodical  hepatitis  B immunoglobulin  (HBIG)  injection  to the mothers,  the  safety  of
antiviral  prophylaxis  with  nucleoside/nucleotide  analogs,  the  beneﬁt  of  different  delivery  ways,  and  the
safety  of breastfeeding.  In  this  review,  we  highlight  these  unsettled  issues  of  preventive  strategies  in
perinatal  period,  and  we further  aim to provide  an  optimal  approach  to the  management  of  preventing
MTCT  of  HBV  infection.©  2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
Chronic hepatitis B virus (HBV) infection is an important global
ealth problem. According to World Health Organization (WHO)
stimates, more than 240 million people worldwide are chronically
nfected with HBV [1,2]. Most of them acquire their infections dur-
ng the perinatal period or in early childhood, especially in highly
ndemic areas [3–5]. Even in areas with low endemicity, perina-
al or early childhood transmission may  account for more than one
hird of chronic infections [1,2,6]. According to previous studies
1,3,7], newborns have 90% chance to become chronic carriers after
nfection with HBV and in children less than 3 years old the chance
s up to 50%, but in adults the chance is only up to 5%. For this rea-
on, vertical transmission, also called mother to child transmission
MTCT), during pregnancy or perinatal periods, has been recog-
ized as the most important phase for the prevention of chronic
BV infection. In China, the rate of HBV infection among women of
hildbearing age is still at a high level (7.18%) [8], indicating that
omen of childbearing age with chronic HBV infection remain a
rucial source of HBV transmission. Therefore, effective prevent-
ng MTCT of HBV from pregnant women to their newborns within
he perinatal period is a promising efﬁcient approach to interrupt
hronic HBV infection [7].
Based on the mechanisms of MTCT of HBV, several strategies
ave already been invited for the prevention of HBV infection dur-
ng perinatal period. HBV vaccination has been adopted in the
ational immunization program in China and many other coun-
ries, and administration of vaccination combined with hepatitis B
mmunoglobulin (HBIG) within 12 h after birth has been applied as
tandard procedures for newborns from HBV positive mothers [2].
ucleoside/nucleotide analogs have proved to be useful and rela-
ively safe in reducing the incidence of MTCT in pregnant women
ith high HBV DNA load [2,9]. These efforts decreased the inci-
ence of carrier rate dramatically in the past years. However, it is
till far away from completely eradicating MTCT of HBV because of
mall part of individuals (around 10%) with intrauterine infection
nd immunoprophylaxis failure [7,9].
Management of HBV infection in pregnancy is difﬁcult because
f several peculiar and somewhat controversial aspects. These chal-
enges include: (1) the failure of passive-active immunoprophylaxis
n a small part of newborns, (2) the effect and necessity of peri-
dical HBIG injection to the mothers, (3) the safety of antiviral
rophylaxis with nucleoside/nucleotide analogs, (4) the beneﬁt of
ifferent delivery ways, (5) the safety of breastfeeding. This review
ill focus on these issues and provide an optimal approach to the
BV management of preventing MTCT.
. Mechanisms of MTCT of HBV
Understanding the mechanisms of MTCT is essential for the
anagement of chronic HBV infection, we will brieﬂy discuss it
rst. Perinatal transimission has been recognized as the main mode
f HBV transmission. There are three possible routes of transmis-
ion: transplacental transmission of HBV in utero (intrauterine
ransmission), natal transimission during delivery (intrapartum
ransmission) and postnatal transmission during care or through
reast milk (postpartum transmission) [7,10,11].
.1. Intrauterine transmission
Intrauterine transmission of HBV is considered to be the most
mportant reason for the failure of passive-active immunopro-
hylaxis in preventing MTCT [7,9]. Different diagnostic criteria
12–20] had been applied for the diagnosis of HBV intrauterine
nfection. Since there is no consensus on the diagnosis criteriairology 77 (2016) 32–39 33
of HBV intrauterine infection, different proofs that could iden-
tify the existence of HBV components in serum of newborns had
been used (Table 1). The exact mechanism of intrauterine trans-
mission of HBV remains to be illuminated. The most frequently
mentioned hypotheses involve: (a) serum/body ﬂuid transmission,
which usually occurs in conditions of placenta damage caused by
contraction of the uterine muscle such as threatened abortion [21],
invasive procedures into the uterus like amniocentesis during preg-
nancy [22] or speciﬁc infections like TORCH (Toxoplasma, Rubella,
Cytomegalovirus and Herpes Simplex) infection; (b) cellular trans-
mission, which refers to transmission of HBV from the maternal
side to the fetal side through placenta cells and transfer of infected
peripheral blood mononuclear cell (PBMC) [15] from the maternal
circulation system into the fetal circulation system; and (c) genetic
transmission, germ cells like sperm and oocytes could be infected
by HBV and transferred the virus to the embryo [23,24].
Accumulated proofs have identiﬁed that high serum HBV DNA
levels and HBeAg positive status in pregnant mothers are key
factors for indicating the increased risk of MTCT of HBV, espe-
cially in intrauterine transmission of HBV through villous capillary
endothelial cells [25–27]. Wiseman et al. [28] have shown a trans-
mission rate of 9% for newborns born from mothers with virus
load > 8 log10 copies/ml (7.3 log10 IU/ml) despite standard passive-
active immunoprophylaxis administration and no transmission
below this cut-off. Recent studies even proposed a lower level of
6 log10 copies/ml (5.3 log10 IU/ml) of maternal viremia as the cut-off
[29,30] and the reported rate [15,31] of MTCT of HBV to newborns
ranged from 8% to nearly 30% if maternal HBV DNA levels are higher
than 6 log10 copies/ml (5.3 log10 IU/ml).
HBeAg positivity is another independent risk factor for the MTCT
of HBV. In fact, HBeAg can pass through the placenta via par-
tial placental leakage or via the “cellular route”. The absence of
HBeAg expression is associated with lower levels of viral replica-
tion and with a signiﬁcantly lower risk of intrauterine transmission
of HBV. [32] These data presume that antiviral therapy with nucleo-
side/nucleotide analogs can decrease viral loads of HBV, which may
be effective to reduce the risk of intrauterine transmission. In addi-
tion, perinatal infection with the immunoprophylaxis occurred in
0.4% (0.0–2.5%) in infants born to HBeAg-negative-carrier mothers
[33]. And previous studies have suggested that anti-HBe-positive
women infect their infants only if they have high HBV viremia levels
[34], and HBV mutants in the precore and/or core regions in some
anti-HBe-positive carrier mothers, leading to be unable to synthe-
size the HBeAg, may  transmit fulminant hepatitis B to their infants
[35–38]. However, the role of precore and/or core mutation is not
very well documented in MTCT.
2.2. Intrapartum transmission
Intrapartum transmission refers to transmission occurring dur-
ing childbirth and it is recognized as the most important route of
HBV MTCT in the state of nature. During the process of delivery,
newborns may  have the chance to be exposed to maternal body
ﬂuids or blood that contains HBV at the time when they pass the
maternal genital tract [9]. And also in case of threatened preterm
labor the contractions of the uterus may cause the laceration of the
placenta and subsequently resulting in entering of maternal blood
into fetal circulation [7].
2.3. Puerperal transmission
Puerperal transmission means infection of HBV due to con-
tact with maternal breast milk, body ﬂuids, blood or other
close contacts between newborns and mothers after delivery
[7,9]. It is subordinate to other transmission routes mentioned
before for its incidence is very low after universal passive-active
34 P. Yi et al. / Journal of Clinical Virology 77 (2016) 32–39
Table 1
Diagnosis criteria of HBV intrauterine infection.
Reference Diagnosis criteria
Chau et al. [13] and Goudeau et al. [12] Persistent serum anti-HBc IgM positive after birth
Beasley et al. [14] High titers of HBsAg within 24 h of birth and after the completion of HBIG and vaccine immunoprophylaxis
Xu  et al. [15] Pre-S1 protein positive in umbilical blood
Li  et al. [16] HBsAg and/or HBeAg positive, or HBV DNA positive in neonatal peripheral blood
Vermeulen et al. [17] Peripheral blood HBV DNA positive
n 24 h
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Zhang  et al. [19] HBV DNA or HBsAg d
Xu  et al. [20] Positive for HBsAg, H
mmunoprophylaxis of newborns born from HBsAg positive moth-
rs was performed.
. Strategies for preventing MTCT of HBV
Prevention of MTCT of HBV is based on its mechanisms. The
trategies include the treatments for mothers during pregnancy
nd efforts for both newborns and their mothers after birth.
.1. Immunoprophylaxis provided to newborns
Immunoprophylaxis provided to newborns clearly reduces the
ncidence of perinatal HBV transmission. With the administration
f infant universal vaccination, the incidence of HBsAg declined
rom 9–12% to <1% in China [39]. Many studies including Cochrane
ystematic reviews indicate that vaccination alone is insufﬁcient
o prevent MTCT of HBV in these HBsAg positive mothers, while
ombination of Hepatitis B vaccine with HBIG has been proved
o be more efﬁcient in reducing MTCT prevalence than vaccine or
BIG alone [40–43]. WHO  guidelines also stated that HBIG con-
unct with vaccination may  be of additional beneﬁt for infants
rom mothers who are HBsAg-positive, particularly if they are also
BeAg-positive [44]. The transmission rate of HBV has decreased
5–95% by universal passive and active immunoprophylaxis of
ewborns [30]. Thus, WHO  and most guidelines suggested that
ewborns from HBsAg positive mothers should receive both HBIG
nd Hepatitis B vaccine within 12 h after delivery, and the complete
mmunoprophylaxis process also includes at least two  more doses
f HBV vaccine at 1 month and 6 month after birth [42,45,46].
Howerve, whether it is necessary for infants born from HBsAg
ositive but HBeAg negative mothers to apply HBIG with vaccine
emains to be established. Data from a recent systematic review
nd meta-analysis show that vaccine alone seems to be equally
ffective to the combination of HBIG and vaccine for neonates of
BsAg-positive and HBeAg-negative mothers in preventing MTCT
f HBV infection [47]. More evidences are needed to warrant on
he addition of HBIG to vaccine for infants of HBsAg-positive but
BeAg-negative mothers. So far, WHO  guidelines stated that, pro-
ection against MTCT achieved by immediate vaccination against
BV may  not be signiﬁcantly improved by the addition of HBIG, in
ull-term neonates whose mothers are HBsAg-positive but HBeAg-
egative [44].
In addition, HBIG may  not be feasible in most settings, due to
oncerns related to supply, safety and cost. Studies have showed
hat administration of a 3 or 4 dose series of hepatitis B vaccine
ithout HBIG has a protective efﬁcacy of 70–95% in mothers who
ere both HBsAg and HBeAg positive [14,48,49]. Some studies have
hown that when HBIG is unavailable, vaccination alone can pre-
ent vertical transmission in 66–90% of cases [50]. A systematic
eview found vaccination reduced the occurrence of hepatitis B
risk ratio 0.28, 95% conﬁdence interval 0.20–0.40), compared with
lacebo or no intervention [41]. These ﬁndings are supportive to
lternatively use Hepatitis B vaccine alone in settings where ﬁnan-
ially constraints the use of HBIG.ours, and/or 1 month, followed by HBsAg positive at 6 months
ble in peripheral serum samples of infants at 52 weeks
A in serum, or HBV DNA in PBMCs tested within 24 h after birth
Despite standard passive-active immunoprophylaxis regimen
in neonates, MTCT of HBV may  still occur in 1–15% of children born
from HBsAg-positive mothers, especially those carrying HBeAg
[4,43,51–53]. One of the great causes of vaccine failure is related to
intrauterine infection [51,54,55]. Reasons for the failure of HBV vac-
cine in stimulating the host to produce speciﬁc antibodies against
HBV are complicated and not yet clearly elucidated. The factors
involved include: (1) the immune tolerance caused by low levels
of HBV infection before injection of HBV vaccine and this usually
happens in uterus during pregnancy [56]; (2) the mutation of HBV S
gene [57]; (3) low activity of IL-2 and related deﬁciency of immune
functions [58,59]; (4) HLA hereditary types and the genes corre-
lated with unresponsiveness of HBV vaccine are HLA-DP, HLA-DQ
and HLA-DR [60]; (5) Deﬁciency of vaccines. The present Hepatitis
B vaccine of multidose prolonged regimens remains some per-
sons who fail to achieve adequate protection. While, recombinant
vaccine containing S, preS1 and preS2 antigens could signiﬁcantly
increase reaction rates of HBV vaccine [61].
3.2. Antiviral prophylaxis with nucleoside/nucleotide analogs
As previously mentioned, high HBV DNA level and HBeAg
positive status in pregnant women are considered as the most
important risk factors for MTCT of HBV. The HBV  transmission
rate in newborns born from HBeAg positive mothers has decreased
from >90% to approximately 3–7% by the combination of HBIG and
HBV vaccine administration [14,41,62,63]. However, other studies
show that the failure rate of immunoprophylaxis in newborns born
from mothers with HBeAg positive and high HBV reaches to 8–32%
[28,64,65]. Thus lowering the level of maternal HBV DNA during
pregnancy is momentous for the prevention of MTCT in mothers
with high viremia.
Among the current oral anti-HBV drugs, telbivudine and teno-
fovir have a pregnancy category B designation. Lamivudine has
been successfully used in preventing MTCT of HIV in pregnant
women for a relatively long time and proved to be a safe agent
during pregnancy although it carries a pregnancy category C classi-
ﬁcation. Thus, lamivudine, telbivudine and tenofovir are currently
available options for pregnant mothers with HBV infection. Plenty
of studies have been explored the possibility of antiviral therapy
in reducing MTCT of HBV in mothers with high serum HBV DNA
levels during the second or third trimester of pregnancy based on
standard passive–active immunoprophylaxis of newborns [32].
Lamivudine is the longest used antiviral drugs in the treat-
ment of pregnant chronic hepatitis B patients. In 2009, a large
randomized, double-blind placebo-controlled trial was performed
to evaluated the efﬁcacy of lamivudine administration to pre-
vent MTCT in pregnant women with HBeAg positive and HBV
DNA > 9 log10 copies/ml (8.3 log10 IU/ml) from week 32 of gesta-
tion to week 4 postpartum [64]. All newborns received standard
passive-active immunoprophylaxis. For a major problem of loss
to follow-up, data showed only a trend but no signiﬁcant differ-
ence in the prevalence of MTCT (6% lamivudine vs. 12% placebo,
p = 0.37) [64]. However, Yu et al. [66] also explored the efﬁcacy and
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afety of lamivudine in 100 pregnant women with HBeAg positive
nd HBV DNA levels >7 log10 copies/ml (6.3 log10 IU/ml) at week
4–32 of gestation. All neonates were also administrated stan-
ard passive–active immunoprophylaxis. Result showed that the
TCT rates were 0% and 7% in lamivudine group and control group
espectively (p < 0.05). However, a recent observational study in
ustralia suggested that a low barrier to resistance of lamivudine
lso can be observed as lamivudine administration started in the
hird trimester of pregnancy and stopped shortly after delivery
67]. In the study, 21 women with high viral load of >7 log10 IU/ml
ere treated with lamivudine for an average duration of 53 days.
t the end of treatment, the median decrease in viral load was
.6 log10 IU/ml, but HBV-DNA remained >7 log10 IU/ml in 18% of
ases. Notably, viral variants with reduced sensitivity to lamivudine
ere observed in 4 women (19%). Therefore, lamivudine adminis-
ration during the third trimester has poor antiviral activity with a
isk of selecting resistance mutations. Currently lamivudine is no
onger a ﬁrst-line option for the treatment of chronic hepatitis B
atients because of the high resistant rate. Thus, its application in
regnant women during the third trimester of pregnancy should
e carefully assessed for the same reason.
Compared with lamivudine, telbivudine is a newly developed
nti-viral agent that has higher efﬁcacy and resistance barrier
68–70]. A large prospective open label study with 229 HBV DNA
7 log10 copies/ml (6.3 log10 IU/ml) and HBeAg-positive pregnant
omen was carried out in China [71]. One hundred and thirty-
ve mothers received telbivudine from 20–32 weeks of gestation
o 1 month postpartum or continuous treatment after delivery
f necessary, while 94 mothers served as controls. All infants
eceived standard passive–active immunoprophylaxis. Prior to
elivery, all telbivudine-treated mothers obtained a more than
 log10 copies/ml decline of the viral load, whereas HBV DNA lev-
ls in untreated mothers remained unchanged. The incidence of
BsAg-positive neonates at 7 months of age was  0% in the tel-
ivudine arm compared to 8% in untreated arm (p = 0.02). A later
eta-analysis that evaluated 6 trails with a total of 576 pregnant
omen showed that telbivudine administrated in late pregnancy is
ffective in reducing MTCT, and no signiﬁcant adverse effects were
bserved [72]. However, this study only enrolled 2 randomized
ontrolled trials with a limited sample size. In a recent well orga-
ized observational study in China, 252HBeAg-positive mothers
ith HBV DNA >6 log10 copies/ml (5.3 log10 IU/ml) received telbivu-
ine at gestation week 28 until postpartum week 4 and 345 mothers
ith matched characteristics but without antiviral agents served as
ontrols [19]. The rate of MTCT in the telbivudine treated group is
% vs. 2.84% in the untreated group (p = 0.002). Other data from
everal latest studies carried out in China [73,74] similarly support
hat telbivudine signiﬁcantly reduces vertical transmission of HBV
ithout evident adverse effects. However, high quality, large-sized
nd randomized controlled trials are needed to conﬁrm efﬁcacy and
afety of telbivudine administration in high viral load mothers in
ate pregnancy to prevent MTCT of HBV.
Tenofovir has been safely used in pregnant women with
IV infection [75]. Based on its high antiviral activity, high
arrier to resistance and safety, tenofovir is expected to be effec-
ive in preventing MTCT of HBV [76]. In a retrospective study,
1 of 45 enrolled HBeAg-positive pregnant women with HBV
NA > 7 log10 copies/ml (6.3 log10 IU/ml) were treated with teno-
ovir from week 18–27 of gestation, and 24 of them were untreated
s controls [77]. All newborns received combined passive–active
rophylaxis. The rate of MTCT of HBV in the treated groups was
% compared to 8.3% in the untreated controls (p = 0.022) and
o signiﬁcant adverse effects were observed. In recent years sev-
ral prospective studies about efﬁcacy and safety of tenofovir in
regnant women were conducted. Greenup et al. [78] enrolled 58
regnant women taking tenofovir from 32 weeks of pregnancyirology 77 (2016) 32–39 35
till 4–12 weeks after delivery and 20 pregnant women receiv-
ing no intervention as controls. Tenofovir signiﬁcantly reduced
maternal viral load with a mean reduction of 3.64 ± 0.9 log10 IU/ml
and dramatically decreased incidence of MTCT of HBV at deliv-
ery. The rate of MTCT was 2% in tenofovir group compared with
20% in control group. The limitation of this study is the high
loss of follow-up rates in newborns (50% in control and 24.1% in
tenofovir group). A better organized prospective multi-center trial
carried out in Taiwan by Chen et al. [79] enrolled 118HBsAg- and
HBeAg- double positive pregnant women  with high HBV DNA  load
of >7.5 log10 IU/ml. Among these mothers, 62 received tenofovir
from 30–32 weeks of pregnancy till 1 month after delivery and 56
received no antiviral agent served as control group. Tenofovir treat-
ment distinctly decreased maternal HBV DNA levels and reduced
perinatal transmission rate. At delivery, maternal HBV DNA was
4.29 ± 0.93 log10 IU/ml (vs. 8.10 ± 0.56 log10 IU/ml in control group,
p < 0.0001) and HBV DNA positivity rate in newborns was  6.15%
(vs. 31.48% in control group, p = 0.0003). HBsAg positive rate in 6
months old infants in tenofovir group was  1.54% (vs. 10.71% in con-
trol group, p = 0.0481). Due to its effectiveness and good tolerability,
tenofovir is promising to be considered to be one of the ﬁrst-line
options for pregnant women with high levels of HBV DNA.
Although report from the antiretroviral pregnancy registry
(APR) [80] and other studies suggested that the overall risk of major
birth defects of newborns in lamivudine and tenofovir treated
mothers is similar to the general population, to date no long-term
infant growth data are available. Lamivudine has been used in
pregnant women for the longest time and more safety data were
accumulated. According to APR data, lamivudine taken in the ﬁrst
trimester resulted in a 1.5-fold increase in risk of overall major
birth defects. For the use of emtricitabine and tenofovir in the
same period during pregnancy, the risk of birth defects would be
at least 2-fold than general population [80,81]. The ﬁrst and the
second trimester are more important than the third trimester for
the development of fetal organs, so the initiation of anti-viral ther-
apy is recommended in the third trimester that helps to minimize
the effect of these drugs to fetal development. Entecavir and teno-
fovir are more effective and have a higher barrier of resistance.
But currently studies about the safety of entecavir in pregnant
HBV DNA positive women and their offspring are unavailable. The
potential toxicity of these antiviral agents and its effect on the
growth of exposed newborns and pregnant women still need fur-
ther large, long and appropriately designed clinical studies. For
these concerns, the American Association for the Study of Liver Dis-
eases (AASLD) concludes that more safety data are required before
administration with these anti-viral drugs for the prevention of
MTCT of HBV could be recommended [82].
Based on the accumulated ﬁndings, for the pregnant women
with high viremia, new guidelines from the European Associ-
ation for the Study of the Liver (EASL) and the Asian Paciﬁc
Association for the Study of the Liver (APASL) indicate that, in
addition to neonatal immunoprophylaxis, treating with antiviral
agents such as tenofovir or telbivudine during pregnancy begin-
ning at 28–32 weeks of gestation may  be safe and effective in
preventing MTCT [83]. However, there is still a research gap to
determine the optimal threshold of HBV DNA for antiviral therapy.
As previously described, a viral load of HBV DNA > 6 log10 copies/ml
(5.3 log10 IU/ml) has been regarded as the main risk of perina-
tal transmission, and the transmission risk increases with a prior
child with passive–active immunoprophylaxis failure [31,84,85].
Thus, we recommend antiviral therapy may  be applied for preg-
nant women with HBV DNA > 6 log10 copies/ml (5.3 log10 IU/ml)
or with previous child who occurred perinatal transmission after
passive–active immunoprophylaxis failure (Fig. 1). In addition, it is
also unsettled to determine the risk of exacerbation or post-partum
ﬂare in the mothers after cessation of antiviral therapy, as well as
36 P. Yi et al. / Journal of Clinical Virology 77 (2016) 32–39
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o establish the optimal duration of continuation of therapy post
artum (4 weeks or 12 weeks). Thus, WHO  recently proposes that
ntiviral therapy would be for a limited period for the purpose of
educing MTCT. If a woman requires treatment based on her own
linical condition then that treatment would be continued through
he pregnancy [44]. Discontinuation of therapy at any point during
r after pregnancy should require serially monitoring of ALT and
BV DNA levels due to the potential for ﬂares upon withdrawal
31,84,85].
.3. Periodical HBIG administration during pregnancy
Whether periodical HBIG administration during the third
rimester of pregnancy in asymptomatic HBsAg positive pregnant
omen impacts on preventing MTCT of HBV or not is controver-
ial. Researchers who support the viewpoint believe that multiple
mall doses of intramuscular HBIG injection could provide passive
mmunization by neutralizing maternal HBV directly. What’s more,
t could activate the immune system by binding with HBsAg and
esults in decreasing HBV replication and HBV DNA load to a cer-
ain extent. This will subsequently reduce the prevalence of HBV in
ewborns and/or increase their HBsAb positive rate. Several studies
n China [27,86] and some meta-analyses [87,88] supported the use
f HBIG during pregnancy. However these meta-analyses had limi-
ations that they ignored the random principle or the imbalance of
BeAg status in the involved pregnant women as well as the serious
eterogeneity involving study qualities, patients’ infectious status
r dosages of HBIG [4,89].
Subsequent studies and meta-analyses produced divergent
esults. [43] They found no signiﬁcant decrease in maternal HBV
NA after the administration of HBIG in HBV carrier mothers dur-
ng pregnancy. In addition, none of their infants was  HBsAb positiveBsAb, hepatitis B surface antibody; ALT, alanine aminotransferase; HBV, hepatitis B
 transmission; HBIG, hepatitis B immunoglobulin.
[90]. Even in studies in which infants’ HBsAb were detected, there
was no difference in HBsAb positive rate in infants at more than 7
months of age between mothers with or without HBIG interven-
tion during pregnancy [89,91]. The possible reasons for not using
periodical HBIG administration during pregnancy include: (1) the
half-life of HBIG is short, therefore, its neutralization efﬁcacy is lim-
ited and transient [92]. (2) Small dosage of HBIG injection (200 IU
or 400 IU) is invalid in decreasing maternal HBV load and insufﬁ-
cient for HBIG to enter the fetal circulation. Although experience
from liver transplantation patients suggested that a continuous
serum concentration of 100–500 IU/l of HBIG is sufﬁcient for the
neutralizing of HBV in the blood [92], in liver transplanted patients
the infected liver had been replaced by a HBV negative one and
they were given very large doses of HBIG, which is quite different
from the conditions of these pregnant mothers. (3) Massive HBIG
injection may  cause HBV mutation, leading to immune resistance
to HBV strains [9,89]. This will subsequently result in the fail-
ure of passive–active immunoprophylaxis and increased resistance
of mutative virus to antiviral agents. Consequently, the periodic
administration of HBIG to the mother to prevent vertical transmis-
sion is currently not recommended. [42] More qualiﬁed data are
needed to demonstrate the effect of HBIG injection during preg-
nancy.
3.4. Different delivery ways and procedures in delivery
The delivery way  to maximumly reduce the incidence of MTCT of
HBV remains controversial. In the past, vaginal delivery was con-
sidered to increase the chance of HBV MTCT, for infant mucosal
membrane directly contacts with the maternal ﬂuids or blood.
This hypothesis is supported by recent studies [93]. Guo et al.
[94] showed that cesarean delivery decreased the risk of MTCT of
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BV. On the contrary, other studies concluded that there is no dif-
erence in the incidence of MTCT between cesarean and vaginal
elivery. One study observed HBsAg-positive mothers’ infants for
 relatively long time and found that at 12 months after birth the
BsAg levels of infants with different delivery ways were not dis-
inct [95]. Since these results were conﬂicting, there is not enough
vidence to support that cesarean delivery is better in avoiding
TCT of HBV compared with vaginal delivery. In view of many
eneﬁts of vaginal delivery compared with cesarean delivery and
he approving effects of passive-active immunoprophylaxis in new-
orns, cesarean delivery is not recommended in HBsAg-positive
others. Elective cesarean delivery is suggested to be started before
he onset of labor and rupture of membrane if it has to be chosen
or other reasons in order to avoid possibility of transmission in
BsAg-positive mothers.
Several measures are considered to be available to reduce the
nfection rate of HBV in labor. These measures include early and
uick cleaning of the respiratory tract, mouth and skin of the new-
orns after delivery. This process will decrease exposure chance of
etus to their maternal amniotic ﬂuid, serum and vaginal discharges
95]. Also procedures that may  damage the integrity of fetal skin,
ike blood sampling, should be avoided.
. Safety of breastfeeding in MTCT of HBV
Currently, the presence of HBsAg, HBeAg and HBV DNA in
reast milk is conﬁrmed. However, plenty of studies indicated
hat based on implementation of immunoprophylaxis, breastfeed-
ng of infants by HBsAg-positive mothers has no additional risk
o MTCT of HBV infection [42,52,96–99]. Hill et al. [96] reported
hat breastfeeding of infants by HBsAg-positive mothers did not
ncrease the infection rate of HBV compared with formula feed
nfants. A meta-analysis of 1624 infants supported that breastfeed-
ng did not increase the risk of MTCT [100]. In a recent multi-center
tudy in China [25], 1186HBsAg-carrier mothers and their infants
ged 8–12 months were followed, yielded a same conclusion. In a
ecent study, exposure to a larger amount of HBV infectious parti-
les via breast milk was detected, but the child correctly vaccinated
as not infected with HBV, indicating breastfeeding may  not be a
ontraindication in HBV-positive mothers after standard immuno-
rophylaxis of their infants [101]. It was supported by current
uidelines [7,44,102–104].
However, little is known about the effects on the infant
f exposure to NAs during breastfeeding [101,102]. Guidelines
rom EASL and other organizations deem that the safety of
ucleoside/nucleotide analogs therapy during lactation is uncer-
ain [84,103]. Since breastfeeding is advantageous, especially in
ow-income countries where HBV is highly endemic, this recom-
endation is thorny. Nonetheless, it is somewhat counterintuitive
nd controversial, in light of the fact that the chance for exposure of
nfants to drugs in utero are likely higher than that through breast
ilk, but these drugs are recommended for use during pregnancy.
oreover, WHO  guidelines state that HIV infected women  could
ontinue antiretroviral treatment during breastfeeding [105]. Data
rom some HIV patients identiﬁed that the dose of tenofovir taken
ia breastfeeding by an infant of 3 kg weight is just 0.03% of the
ose used in preventing of HIV transmission in infants [105–107].
imilar studies indicate that the exposure to lamivudine or teno-
ovir is lower from breastfeeding than from in utero exposure [107].
hus, these data do not support the contraindication to use antiviral
gents during breastfeeding. Further clinical studies are required to
valuate the safety of breastfeeding in mothers on antiviral therapy.
The end point of antiviral therapy aimed to reduce the risk
f MTCT is typically in the immediate postpartum period, usu-
lly around 4 weeks after delivery, for mothers who meet theirology 77 (2016) 32–39 37
criteria for withdrawal of anti-viral drugs and plan to breastfeed
their infants [108].
5. Conclusion
HBV infection in pregnancy is not only a unique challenge but
also an important opportunity to prevent MTCT of HBV. Since
conducting of double-blinded, randomized trails is not feasible in
reality in pregnant women for ethical and other reasons, most of our
data were obtained from open-labeled and non-randomized retro-
spective or prospective studies. Fortunately, lots of studies have
reached relative consensuses and there are several procedures that
are generally accepted to be feasible (shown in Fig. 1). Standard
passive–active immunoprophylaxis with HBIG plus HBV vaccine in
neonates within 12 h after delivery is proved to be successful in
preventing approximately 90% of newborns from MTCT of HBV. For
up to 9% of newborns suffered from MTCT of HBV after standard
immunoprophylaxis, the main reason is perinatal transmission of
HBV associated with high levels of viremia in mothers (serum
HBV DNA ≥ 6 log10 copies/ml or 5.3 log10 IU/ml). Administration of
antiviral agents such as tenofovir or telbivudine during pregnancy
beginning at 28–32 weeks of gestation is reasonable in high viremic
pregnancies. Based on standard passive–active immunoprophy-
laxis regimen, breastfeeding is recommended in HBsAg-positive
mothers. There are still some controversial issues that need further
concerns, including breastfeeding of infants by mothers on antiviral
therapy, HBIG injection during pregnancy and the potential long-
term side effect of antiviral agents to both HBV positive mothers
and their infants.
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